Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| AE, AEs | Adverse event |
| AF | Aggressive fibromatosis |
| AHFS | American Hospital Formulary Service |
| ALT | Alanine aminotransferase |
| AMH | Anti-Mullerian hormone |
| ANCOVA | Analysis of covariance |
| aOR | Adjusted odds ratio |
| APC | Adenomatous polyposis coli |
| API | Application programming interface |
| ARR | Absolute risk reduction |
| AS | Active surveillance |
| ASCO | American Society of Clinical Oncology |
| AST | Aspartate aminotransferase |
| ASTs | Advanced solid tumors |
| AT | Active treatment |
| ATU | Awareness, trial and usage |
| AUC | Area under the concentration-time curve |
| AUC0-inf | Area under the concentration-time curve from time 0 extrapolated to infinity |
| AUC0-t | Area under the concentration-time curve from time 0 to the last observed non-zero concentration |
| AUCtau | Area under the concentration-time curve over the dosing interval |
| AV | Atrioventricular |
| AW | Abdominal wall |
| BE | Bioequivalence |
| BICR | Blinded independent central review |
| BIW | Twice weekly |
| BMI | Body mass index |
| BMS | Bristol-Myers Squibb |
| BPI | Brief pain inventory |
| C1 | Cycle 1 |
| CAR | Clinical and radiologic |
| Cavg | Average concentration |
| CBC | Complete blood count |
| CDK4 | Cyclin-dependent kinase 4 |
| CE | Concept elicitation |
| CI | Confidence interval |
| Cmax | Maximum observed concentration |
| CMP | Comprehensive metabolic panel |
| COX-2 | Cyclooxygenase-2 |
| CR, CRs | Complete response; complete remission |
| CrCl | Creatinine clearance |
| CT | Computed tomography |
| CTCAE | Common Terminology Criteria for Adverse Events |
| CTNNB1 | Beta-catenin gene |
| Ctrough | Concentration before the next administration |
| CYP3A | Cytochrome P450 3A |
| CYP3A4 | Cytochrome P450 3A4 |
| DB | Double-blind |
| DDI | Drug-drug interaction |
| DEE | Doxorubicin eluting embolization |
| DeFi | Desmoid fibromatosis (phase 3 trial of nirogacestat) |
| DF | Desmoid-type fibromatosis |
| DLT, DLTs | Dose-limiting toxicity |
| DOR | Duration of response |
| DT, DTs | Desmoid tumor |
| DTF | Desmoid-type fibromatosis |
| DTF-QoL | Desmoid-Type Fibromatosis Quality of Life questionnaire |
| DTIS | Desmoid Tumor Impact Scale |
| DTRF | Desmoid Tumor Research Foundation |
| DTSS | Desmoid Tumor Symptom Scale |
| DTWG | Desmoid Tumor Working Group |
| E-R, ER | Exposure-response |
| EAG | External assessment group |
| ECG, ECGs | Electrocardiogram |
| ECOG | Eastern Cooperative Oncology Group |
| EDTA | Ethylenediaminetetraacetic acid |
| EFS | Event-free survival |
| EMA | European Medicines Agency |
| EORTC | European Organisation for Research and Treatment of Cancer |
| EPAR | European public assessment report |
| EQ-5D | EuroQol 5-dimensional questionnaire |
| ESAS | Edmonton Symptom Assessment System |
| ESMO | European Society for Medical Oncology |
| EU | European Union |
| FAP | Familial adenomatous polyposis |
| FCT | Film-coated tablets |
| FDA | Food and Drug Administration |
| FEP | Federal Employee Program |
| FORP | Females of reproductive potential |
| FSH | Follicle-stimulating hormone |
| G-BA | Federal Joint Committee (Gemeinsamer Bundesausschuss) |
| G3, G4 | Grade 3, grade 4 |
| GI | Gastrointestinal |
| GISG | German Interdisciplinary Sarcoma Group |
| GIST | Gastrointestinal stromal tumor |
| GODDESS | Gounder/Desmoid Tumor Research Foundation Desmoid Symptom/Impact Scale |
| GP | General practitioner |
| GS | Gamma secretase |
| GSI, GSIs | Gamma secretase inhibitor |
| H2 | Histamine-2 |
| HB | House Bill |
| HES1, Hes1 | Hairy and enhancer of split-1 |
| HI | Hepatic impairment |
| HIFU | High-intensity focused ultrasound |
| HIV | Human immunodeficiency virus |
| HPN | Home parenteral nutrition |
| HR | Hazard ratio |
| HRQL, HRQoL | Health-related quality of life |
| IADTs | Intra-abdominal desmoid tumors |
| IC50s | Median inhibitory concentrations |
| ICD, ICD-10 | International Classification of Diseases; International Classification of Diseases, 10th revision |
| ICER | Incremental cost-effectiveness ratio |
| ICF | Informed consent form |
| IHC | Immunohistochemistry |
| ILP | Isolated limb perfusion |
| INN | International nonproprietary name |
| IP | Investigational product |
| IQR | Interquartile range |
| IRCCS | Istituto di Ricovero e Cura a Carattere Scientifico |
| ISPOR | International Society for Pharmacoeconomics and Outcomes Research |
| ITT | Intention to treat |
| KIT | KIT receptor tyrosine kinase |
| LFTs | Liver function tests |
| LH | Luteinizing hormone |
| LRFS | Local recurrence-free survival |
| LS | Least squares |
| MAA | Marketing Authorization Application |
| MCT, MCTs | Meaningful change threshold |
| MDM2 | Mouse double minute 2 homolog |
| MDT | Multidisciplinary team |
| MedDRA | Medical Dictionary for Regulatory Activities |
| MMRM | Mixed model for repeated measures |
| mRECIST | Modified Response Evaluation Criteria in Solid Tumors |
| MRI | Magnetic resonance imaging |
| MTB | Metabolite |
| MTD | Maximum tolerated dose |
| MTX | Methotrexate |
| MWA | Microwave ablation |
| NCA | Non-compartmental analysis |
| NCCN | National Comprehensive Cancer Network |
| NCODA | National Community Oncology Dispensing Association |
| NDA | New Drug Application |
| NDC | National Drug Code |
| NDRS | National Disease Registration Service |
| NE | Not estimable |
| NF1 | Neurofibromatosis type 1 |
| NF1-PN | Neurofibromatosis type 1-associated plexiform neurofibromas |
| NGS | Next-generation sequencing |
| NHI | National Health Insurance |
| NHS | National Health Service |
| NICE | National Institute for Health and Care Excellence |
| NMA | Network meta-analysis |
| NNT | Number needed to treat |
| NR | Not reached |
| NRS | Numeric rating scale |
| NSAID, NSAIDs | Nonsteroidal anti-inflammatory drug |
| NSCLC | Non-small cell lung cancer |
| OLE | Open-label extension |
| ORR | Objective response rate |
| OS | Overall survival |
| OT | Ovarian toxicity |
| P-gp | P-glycoprotein |
| PAR6mo | Progression arrest rate at 6 months |
| PBO | Placebo |
| PD | Progressive disease; pharmacodynamic |
| PDGFRA | Platelet-derived growth factor receptor alpha |
| PDUFA | Prescription Drug User Fee Act |
| PFS | Progression-free survival |
| PGT-M | Preimplantation genetic testing for monogenic/single gene defects |
| Ph1, Ph2/3 | Phase 1; phase 2/3 |
| PI | Principal investigator |
| PK | Pharmacokinetics |
| PLD | Pegylated liposomal doxorubicin |
| PO | Orally |
| PQI | Positive Quality Intervention |
| PR, PRs | Partial response; partial remission |
| PRO, PROs | Patient-reported outcome |
| PROMIS | Patient-Reported Outcomes Measurement Information System |
| PS | Performance status |
| pts | Patients |
| PV/LPV | Pathogenic or likely pathogenic variants |
| Q-TWiST | Quality-adjusted time without symptoms of disease progression or toxicity |
| Q2 | Second quarter |
| QALY, QALYs | Quality-adjusted life year |
| QD | Once daily |
| QLQ-C30 | Quality of Life Questionnaire Core 30 |
| QoL | Quality of life |
| QTc | QT interval corrected for heart rate |
| QTcF | QT interval corrected for heart rate using Fridericia's formula |
| R0 | Microscopically negative resection margins |
| R1 | Microscopically positive resection margins |
| R2 | Macroscopically incomplete resection |
| rBA | Relative bioavailability |
| RECIST | Response Evaluation Criteria in Solid Tumors |
| RFS | Recurrence-free survival |
| RR | Risk ratio |
| RRePS | Réseau de Référence en Pathologie des Sarcomes |
| RT | Radiotherapy |
| SAEs | Serious adverse events |
| SD | Stable disease; standard deviation |
| SE | Standard error |
| SHI | Statutory health insurance |
| SLD | Sum of longest diameter |
| SOD | Sum of diameters |
| STS | Soft tissue sarcoma |
| T-ALL | T-cell acute lymphoblastic leukemia |
| t1/2 | Terminal elimination half-life |
| T2W | T2-weighted |
| TdP | Torsade de pointes |
| TEAE, TEAEs | Treatment-emergent adverse event |
| TESAEs | Treatment-emergent serious adverse events |
| TFS | Treatment-free survival |
| TGCT | Tenosynovial giant cell tumor |
| TGI | Tumor growth inhibition |
| TKI, TKIs | Tyrosine kinase inhibitor |
| Tmax | Time of maximum observed plasma concentration |
| TNF | Tumor necrosis factor |
| TSS-5 | Total Symptom Score-5 |
| TTV | Total tumor volume |
| TV | Tumor volume |
| UK | United Kingdom |
| ULN | Upper limit of normal |
| UREL | Utility of the time from disease progression until death or end of follow-up |
| US | United States; ultrasound |
| USA | United States of America |
| UTOX | Utility of the time spent with treatment-related toxicity prior to disease progression |
| UTWiST | Utility of the time without progression or toxicity |
| VAR | Varegacestat |
| VBL | Vinblastine |
| vs | Versus |
| WAC | Wholesale acquisition cost |
| WHO | World Health Organisation |
| WNL | Within normal limits |
| WNT | Wingless-related integration site |
| WPI | Worst pain intensity |
| YA | Young adult |